ArticleiScience2025
Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of EGF/EGFR Vaccines in EGFR-Driven Solid Tumors: A Systematic Review and Meta-Analysis of Controlled and Single-Arm Studies.Cancer medicine · 2025Pooled it
- Longitudinal spatial multi-omics delineates tumor microenvironment remodeling across sequential EGFR-TKIs in EGFR-mutant NSCLC.Journal of translational medicine · 2026Article
- Heterogeneous efficacy and predictors of response to immunotherapy in driver-mutant advanced NSCLC: a focus on EGFR and KRAS subtypes.Translational lung cancer research · 2026Article
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
- Prognostic value and therapeutic implications of HMGA2 in EGFR-mutant non-small cell lung cancer.Translational cancer research · 2026Article
- Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.BMC cancer · 2026Article
- Global trends and research progress on immunotherapy forJournal of thoracic disease · 2026Article
- Atlas-Guided Nanocarrier Strategies Targeting Spatial NTRK2/MAPK Signaling in EGFR-TKI-Resistant Niches of Esophageal Squamous Cell Carcinoma.Pharmaceutics · 2026Review
- Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity.Cancer immunology, immunotherapy : CII · 2026Article
- Advances in understanding the mechanisms underlying acquired resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer.Frontiers in cell and developmental biology · 2026Review
- Case Report: Immune checkpoint inhibitor plus chemotherapy benefited an elderly patient with non-small cell lung cancer following EGFR-TKI resistance.Frontiers in oncology · 2026Article
- Mitochondrial niches of residual disease in EGFR-mutant NSCLC: immune-constrained persistence and therapeutic interception.Frontiers in immunology · 2026Review
- Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis.Journal of neuro-oncology · 2025Article
- Spatial microbiome-metabolic crosstalk drives CD8Frontiers in microbiology · 2025Article
- Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.